+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Gender (Male, Female), By Treatment (Pharmaceuticals, Devices), By End-use (Dermatology Clinics, Homecare Settings), By Sales Channel, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • February 2024
  • Region: Global
  • Grand View Research
  • ID: 5943914
Description Jump to:
The global androgenetic alopecia market size is anticipated to reach USD 4.76 billion by 2030 and is anticipated to expand at a CAGR of 8.45% from 2024 to 2030. The growing prevalence of androgenetic alopecia is one of the crucial factors driving the market growth. According to data published by the American Hair Loss Association, over 95% of hair loss in men is caused due to androgenetic alopecia. The occurrence of hair loss in men increases proportionately with age. On the basis of the report published by the International Society of Hair Restoration Surgery, in men, it is estimated that 40% of hair loss is encountered by the age of 35 years, 65% at 60 years, 70% at 80 years, and 80% at the age of 85 years.

Moreover, the market growth can be attributed to advancements in technology, including the introduction of a low-level laser therapy, which helps stimulate hair growth. Likewise, the introduction of several laser combs and hair massagers or brushes is also boosting the market. For instance, Lifemax Infrared Hairbrush, Follinex Massager Comb, and Hairmax Laser Comb are some of the technologically advanced products available in the market. Most clinical-based settings offer combination therapy of non-ablative laser treatment and topical application of medicinal products for better results. Microscopic injuries created by laser devices create a favorable wound-healing environment that triggers hair regrowth.

Furthermore, the increasing incidence of chronic diseases such as cancer is anticipated to offer lucrative opportunities for market growth. For instance, according to the latest report by Globocan, the incidence of cancer was estimated to be 19,288,916 in 2020 globally. Certain medications prescribed to patients for the treatment of cancer are also responsible for hair loss. For instance, chemotherapeutic agents, radiation therapy, hormone therapy, and immunotherapy are more likely to induce hair loss or hair thinning. Cancer incidence is expected to rise by about 70% over the next two decades, thus driving the market growth.

However, reimbursement coverage for androgenetic alopecia treatment is one of the major challenges in this market. Since most treatment modalities for AGA are considered cosmetic procedures and not medically essential ones, they are generally not covered under insurance. Out-of-pocket costs for AGA treatment usually include frequent doctor visits, prescription drug copays, and coinsurance for procedures. Alopecia has complex reimbursement positioning, as it is not a life-threatening disease. For instance, Aetna Inc.’s policy for alopecia states that drugs covered for mild conditions are different from those considered for more severe conditions. In addition, the scheme does not cover Rogaine (minoxidil) as it is considered an experimental therapy. Thus, lack of reimbursement policies for treatment is restraining the market growth.

Androgenetic Alopecia Market Report Highlights

  • The male segment dominated the market in 2023 due to the high adoption of androgenetic alopecia treatments
  • The pharmaceuticals segment held the largest share in 2023. The increasing number of product approvals, rising investments by pharmaceutical companies, and shift in societal attitude toward adopting pharmaceutical drugs for the treatment of androgenetic alopecia are likely to play a prominent role in segment growth
  • The devices treatment segment is expected to grow at the fastest CAGR over the forecast period
  • The dermatology clinics end-use segment accounted for the largest revenue share in 2023 owing to increased consumer awareness regarding prescription medicines & modern treatments, such as laser technology, coupled with a strong product pipeline
  • North America held a dominant revenue share in 2023 due to the high disease prevalence, consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure
  • In November 2023, Sun Pharma Advanced Research Company (SPARC) entered into an agreement with Johns Hopkins and the Czech research institute IOCB to exclusively license SCD-153, including all patents owned by IOCB

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Gender
1.2.2. Treatment
1.2.3. End Use
1.2.4. Sales Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Gender outlook
2.2.2. Treatment outlook
2.2.3. End use outlook
2.2.4. Sales channel outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Androgenetic Alopecia Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of androgenic alopecia
3.2.1.2. Technological advancements in androgenic alopecia
3.2.2. Market restraint analysis
3.2.2.1. Lack of reimbursement policies for androgenic alopecia
3.2.3. Market opportunity analysis
3.2.3.1. Increasing prevalence of chronic diseases
3.3. Androgenetic Alopecia Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Androgenetic Alopecia Market: Prevalence Data, By Region
3.4.1. North America
3.4.1.1. U.S.
3.4.1.2. Canada
3.4.2. Europe
3.4.2.1. UK
3.4.2.2. Germany
3.4.2.3. France
3.4.2.4. Italy
3.4.2.5. Spain
3.4.2.6. Denmark
3.4.2.7. Sweden
3.4.2.8. Norway
3.4.3. Asia Pacific
3.4.3.1. Japan
3.4.3.2. China
3.4.3.3. India
3.4.3.4. South Korea
3.4.3.5. Australia
3.4.3.6. Thailand
3.4.4. Latin America
3.4.4.1. Brazil
3.4.4.2. Mexico
3.4.4.3. Argentina
3.4.5. Middle East and Africa (MEA)
3.4.5.1. South Africa
3.4.5.2. Saudi Arabia
3.4.5.3. UAE
3.4.5.4. Kuwait
Chapter 4. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis
4.1. Gender Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Androgenetic Alopecia Market by Gender Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Male
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Female
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis
5.1. Treatment Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Androgenetic Alopecia Market by Treatment Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Pharmaceuticals
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Devices
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Androgenetic Alopecia Market: End-use Estimates & Trend Analysis
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Androgenetic Alopecia Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Dermatology Clinics
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.2. Homecare Settings
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis
7.1. Sales Channel Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Androgenetic Alopecia Market by Sales Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Prescription
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. OTC
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Androgenetic Alopecia Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7. Asia Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.8.2. Mexico
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9.2. Saudi Arabia
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. Johnson & Johnson Services, Inc.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Cipla, Inc.
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Sun Pharmaceutical Industries Ltd.
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Merck & Co., Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Dr. Reddy’s Laboratories Ltd.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Aurobindo Pharma
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Lexington Intl., LLC
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Curallux, LLC
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Apira Science, Inc. (iGROW Laser)
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
9.3.14. Theradome, Inc.
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Product benchmarking
9.3.14.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America androgenetic alopecia market, by country, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Table 3 North America androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 4 North America androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 5 North America androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 6 North America androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 7 US androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 8 US androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 9 US androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 10 US androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 11 Canada androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 12 Canada androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 13 Canada androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 14 Canada androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 15 Europe androgenetic alopecia market, by country, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Table 16 Europe androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 17 Europe androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 18 Europe androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 20 Germany androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 21 Germany androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 22 Germany androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 23 Germany androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 24 UK androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 25 UK androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 26 UK androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 27 UK androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 28 France androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 29 France androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 30 France androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 31 France androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 32 Italy androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 33 Italy androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 34 Italy androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 35 Italy androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 36 Spain androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 37 Spain androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 38 Spain androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 39 Spain androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 40 Denmark androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 41 Denmark androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 42 Denmark androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 43 Denmark androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 44 Sweden androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 45 Sweden androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 46 Sweden androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 47 Sweden androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 48 Norway androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 49 Norway androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 50 Norway androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 51 Norway androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 52 Asia Pacific androgenetic alopecia market, by country, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Table 53 Asia Pacific androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 54 Asia Pacific androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 55 Asia Pacific androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 57 China androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 58 China androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 59 China androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 60 China androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 61 Japan androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 62 Japan androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 63 Japan androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 64 Japan androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 65 India androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 66 India androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 67 India androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 68 India androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 69 South Korea androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 70 South Korea androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 71 South Korea androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 72 South Korea androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 73 Australia androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 74 Australia androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 75 Australia androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 76 Australia androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 77 Thailand androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 78 Thailand androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 79 Thailand androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 80 Thailand androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 81 Latin America androgenetic alopecia market, by country, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Table 82 Latin America androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 83 Latin America androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 84 Latin America androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 86 Brazil androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 87 Brazil androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 88 Brazil androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 89 Brazil androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 90 Mexico androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 91 Mexico androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 92 Mexico androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 93 Mexico androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 94 Argentina androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 95 Argentina androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 96 Argentina androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 97 Argentina androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 98 MEA androgenetic alopecia market, by country, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Table 99 MEA androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 100 MEA androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 101 MEA androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 102 MEA androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 103 South Africa androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 104 South Africa androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 105 South Africa androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 106 South Africa androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 111 UAE androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 112 UAE androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 113 UAE androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 114 UAE androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 115 Kuwait androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
Table 116 Kuwait androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 117 Kuwait androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 118 Kuwait androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Androgenetic alopecia market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment and end-use segment snapshot
Fig. 10 Sales channel and gender segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Market dynamics
Fig. 13 Prevalence of rheumatoid arthritis in 2022, by WHO regions
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Androgenetic alopecia market: Gender outlook and key takeaways
Fig. 17 Androgenetic alopecia market: Gender movement analysis
Fig. 18 Male market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Female market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Androgenetic alopecia market: Treatment outlook and key takeaways
Fig. 21 Androgenetic alopecia market: Treatment movement analysis
Fig. 22 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Devices market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Androgenetic alopecia market: End-use outlook and key takeaways
Fig. 25 Androgenetic alopecia market: End-use movement analysis
Fig. 26 Dermatology clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Homecare settings market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Androgenetic alopecia market: Sales channels outlook and key takeaways
Fig. 29 Androgenetic alopecia market: Sales channels movement analysis
Fig. 30 Prescription market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 OTC market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Androgenetic alopecia market revenue, by region, 2023 & 2030 (USD Million)
Fig. 33 Regional marketplace: Key takeaways (1/2)
Fig. 34 Regional marketplace: Key takeaways (2/2)
Fig. 35 North America androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 36 Key country dynamics
Fig. 37 U.S. androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 38 Key country dynamics
Fig. 39 Canada androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 40 Europe androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 41 Key country dynamics
Fig. 42 UK androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 43 Key country dynamics
Fig. 44 Germany androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 45 Key country dynamics
Fig. 46 France androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 47 Key country dynamics
Fig. 48 Spain androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 49 Key country dynamics
Fig. 50 Italy androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 51 Key country dynamics
Fig. 52 Denmark androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 53 Key country dynamics
Fig. 54 Sweden androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 55 Key country dynamics
Fig. 56 Norway androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 57 Rest of Europe androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD million) (Number of Patients Treated in Thousands)
Fig. 58 Asia Pacific androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 59 Key country dynamics
Fig. 60 Reimbursement scenario
Fig. 61 Japan androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 62 Key country dynamics
Fig. 63 Regulatory framework
Fig. 64 Reimbursement scenario
Fig. 65 China androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 66 Key country dynamics
Fig. 67 Reimbursement scenario
Fig. 68 India androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 69 Key country dynamics
Fig. 70 Australia androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 71 Key country dynamics
Fig. 72 South Korea androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 73 Key country dynamics
Fig. 74 Thailand androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 75 Key country dynamics
Fig. 76 Malaysia androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 77 Key country dynamics
Fig. 78 Vietnam androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 79 Key country dynamics
Fig. 80 Philippines androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 81 Rest of Asia Pacific androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD million) (Number of Patients Treated in Thousands)
Fig. 82 Latin America androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 83 Key country dynamics
Fig. 84 Brazil regulation details
Fig. 85 Reimbursement scenario
Fig. 86 Brazil androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 87 Key country dynamics
Fig. 88 Argentina pharmaceuticals registration details
Fig. 89 Argentina androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD million) (Number of Patients Treated in Thousands)
Fig. 90 Key country dynamics
Fig. 91 Regulatory framework
Fig. 92 Reimbursement scenario
Fig. 93 Mexico androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 94 Rest of Latin America androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD million) (Number of Patients Treated in Thousands)
Fig. 95 MEA androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 South Africa androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 98 Key country dynamics
Fig. 99 Saudi Arabia androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 100 Key country dynamics
Fig. 101 UAE androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 102 Key country dynamics
Fig. 103 Kuwait androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 104 Key country dynamics
Fig. 105 Turkey androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 106 Rest of MEA androgenetic alopecia market estimates and forecasts, 2018 - 2030 (USD Million) (Number of Patients Treated in Thousands)
Fig. 108 Company market share analysis, 2023
Fig. 109 Strategic framework

Companies Mentioned

  • Johnson & Johnson Services, Inc.
  • Cipla, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma
  • Lexington Intl., LLC
  • Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
  • Curallux, LLC
  • Apira Science, Inc. (iGROW Laser)
  • Theradome, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedFebruary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.72 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.76 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Androgenetic Alopecia Treatment Global Market Report 2024 - Product Image

Androgenetic Alopecia Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Androgenetic Alopecia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Androgenetic Alopecia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 136 Pages
  • Global
From
Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, and Devices), By Gender (Male, and Female), By Sales Channel, By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, and Devices), By Gender (Male, and Female), By Sales Channel, By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • 240 Pages
  • Global
From
Androgenetic Alopecia Market - Product Image

Androgenetic Alopecia Market

  • Report
  • 200 Pages
  • Global
From
Alopecia Market Size, Share & Trends Analysis Report by Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), Treatment, Gender, Sales Channel, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Alopecia Market Size, Share & Trends Analysis Report by Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), Treatment, Gender, Sales Channel, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From

About the Androgenetic Alopecia Market

Androgenetic alopecia, also known as male or female pattern hair loss, is a common form of hair loss affecting both men and women. Although not traditionally categorized as an immune disorder, recent research suggests that immune response may contribute to the pathophysiology of the condition. Immune disorders drugs pertain to therapies that modify or modulate the immune system, some of which have been found to incidentally affect hair growth. For example, drugs initially developed for autoimmune conditions have been observed to stimulate hair regrowth in some patients with alopecia. These observations have led to a growing interest in the potential repurposing of specific immune modulators for the treatment of androgenetic alopecia. The therapeutic approach typically targets immune pathways that may inadvertently suppress hair follicle activity, aiming to either inhibit or regulate immune responses. The therapeutic landscape for androgenetic alopecia within the context of immune disorders drugs includes both off-label use of existing immunomodulatory medications and the development of new therapies specifically geared towards treating hair loss. Some companies that are active in the androgenetic alopecia market include Pfizer, Johnson & Johnson, Merck & Co., and Aclaris Therapeutics. These companies may be involved in the production of existing treatments for androgenetic alopecia such as minoxidil and finasteride, or in the research and development of novel therapies that target the immune aspects of hair loss. The continued research and development in this space reflect an evolving understanding of the complex interactions between the immune Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.